What is the primary indication for using long-acting beta-agonists?

Termination of asthma attacks

Relief of acute bronchospasm

Maintenance treatment of asthma and COPD

Long-acting beta-agonists (LABAs) are primarily indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). These medications work by providing prolonged bronchodilation, making them effective at relaxing the smooth muscles in the airways, thus facilitating improved airflow over extended periods.

In patients with asthma, LABAs are often used in conjunction with inhaled corticosteroids to help control chronic symptoms and reduce the frequency of exacerbations. Similarly, in COPD management, LABAs contribute to maintaining open airways and improving overall lung function, which is essential for patients experiencing chronic airway obstruction.

Using LABAs as a maintenance treatment allows for better long-term control of asthma and COPD symptoms, unlike short-acting agents that are used for immediate relief. This difference in indication reflects the pharmacodynamics and duration of action of LABAs compared to other respiratory medications.

Reduction of respiratory infections

Want more questions?

All options are one-time payments.

$25.99

30 day premium pass

All the basics to get you started

  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 30 day premium pass access
$59.99 $171.99 usd

6 month DELUXE pass (most popular)

Everything with the 30 day premium pass FOR 6 MONTHS! & the ultimate digital PDF study guide (BONUS)

  • Everything included in the premium pass
  • $171.99 usd value for $59.99! You save $106!
  • + Access to the ultimate digital PDF study guide
  • + 6 months of premium pass access
  • + Priority support
$15.99 $24.99

Ultimate digital PDF study guide

For those that prefer a more traditional form of learning

  • Available for instant download
  • Available offline
  • Hundreds of practice multiple choice questions
  • Comprehensive content
  • Detailed explanations
Image Description
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy